Earlier this year, the US Food and Drug Administration (FDA), in partnership with the European Medicines Agency, released 10 guiding principles for the use of artificial intelligence (AI) in drug development.1 Among other things, the principles advise adhering to relevant legal, ethical, technical, scientific, cybersecurity, and regulatory standards; having a well-defined context of use; and using plain language to present clear, accessible, and contextually relevant information to the...